A*STAR Singapore Immunology Network (A*STAR SIgN)

A*STAR researchers discovered a potential new treatment for severe eczema by targeting a protein that regulates immune cell activity.

Antibodies in mucous membranes may be key in protecting against SARS-CoV-2 variants, pointing to the need for COVID-19 vaccines that target these antibody responses.

A high-resolution study of SARS-CoV-2 antibodies revealed how they neutralise variants and reduce the impact of spike protein mutations.

Using artificial intelligence techniques, Mai Chan Lau maps the spatial relationships between tumour cells and immune cells to understand their effect on clinical outcomes.

As the immune system ages, our susceptibility to conditions such as cancer increases, prompting researchers to develop advanced experimental models to study these pathways.

Neutrophils, typically our immune defenders, can paradoxically promote cancer progression when altered in tumours.

Researchers find that targeting nerve growth factor in melanomas transforms resistant ‘cold’ tumours into treatable ‘hot’ ones, adding new therapeutic options for challenging skin cancers.

Through innovative technologies and deep biological insights, A*STAR research institutes and ecosystem partners aim to enhance the healthspan of Asia’s ageing populations.

Lab-grown human brain tissue cultures incorporating immune cells offer never-before-seen insights into the complexity of embryonic brain development.

Research suggests monitoring individuals previously infected with Zika virus for chronic skin diseases caused by overactive T cells.

Researchers identify predictive immune ‘signatures’ in liver cancer patients that can help tailor and improve the success rates of combined immunotherapy and radiotherapy.

While the new Omicron XBB COVID-19 subvariant deftly dodges immune defences even in vaccinated individuals, researchers find that mixed mRNA vaccines may offer a vital boost of protection.